Table 2.
Treatment duration
| DMT | ITP duration (months) | Switch to other DMT | Complete DMT discontinuation | |
|---|---|---|---|---|
| Mean ± SD | Median (IQR) | |||
| Ocrelizumab | 13.71 ± 5.42 | 13 (8–19) | 4 | 0 |
| Alemtuzumab | 13.77 ± 2.62 | 13 (12–15) | 0 | 17 |
| Natalizumab | 15.53 ± 9.65 | 12 (7–24) | 73 | 17 |
| Cladribine | 11.80 ± 3.21 | 13 (12–14) | 0 | 0 |
| Fingolimod | 19.41 ± 9.97 | 19 (11–29) | 135 | 62 |
| Teriflunomide | 19.79 ± 10.74 | 19 (10–30) | 116 | 39 |
| Dimethyl fumarate | 19.10 ± 10.55 | 19 (10–29) | 64 | 64 |
| Interferon beta1a im | 23.73 ± 12.03 | 30 (10–35) | 130 | 17 |
| Interferon beta1b | 24.32 ± 12.32 | 30 (10–35) | 93 | 24 |
| Glatiramer acetate | 23.41 ± 11.24 | 21 (9–34) | 140 | 45 |
| Peg-interferon beta1a | 16.49 ± 10.38 | 15 (7–24) | 85 | 16 |
| Interferon beta1a sc | 21.61 ± 11.50 | 23 (11–34) | 248 | 56 |
Table shows mean (± standard deviation (SD)) and median (and interquartile range (IQR)) of duration of IPTs, and number of patients that were switched to other DMT or were completely discontinued from DMT